Patent landscape of inhibitors and PROTACs of the anti-apoptotic BCL-2 family proteins. (2nd September 2022)

• Record Type: Journal Article
• Authors: Pal, Pratik; Zhang, Peiyi; Poddar, Saikat K.; Zheng, Guangrong
• Is Part Of: Expert opinion on therapeutic patents. Volume 32:Number 9(2022)
• Page Start: 1003
• Page End: 1026
• Publication Date: 2022-09-02
• Subjects: Apoptosis -- BCL-2 protein family -- cancer therapy -- protein–protein interactions -- BH3 mimetics -- PROTACs; Drugs -- Patents -- Periodicals; 615.10272
• DOI: 10.1080/13543776.2022.2116311
• Languages: English
• ISSNs: 1354-3776

Abstract

ABSTRACT: Introduction: The anti-apoptotic BCL-2 family proteins, such as BCL-2, BCL-XL, and MCL-1, are excellent cancer therapeutic targets. The FDA approval of BCL-2 selective inhibitor venetoclax in 2016 validated the strategy of targeting these proteins with BH3 mimetic small molecule inhibitors. Areas covered: This review provides an overview of the patent literature between 2016 and 2021 covering inhibitors and PROTACs of the anti-apoptotic BCL-2 proteins. Expert opinion: Since the FDA approval of venetoclax, tremendous efforts have been made to develop its analogues with improved drug properties. These activities will likely result in new drugs in coming years. Significant progress on MCL-1 inhibitors has also been made, with multiple compounds entering clinical trials. However, MCL-1 inhibition could cause on-target toxicity to normal tissues especially the heart. Similar issue exists with BCL-XL inhibitors, which cause on-target platelet toxicity. To overcome this issue, several strategies have been applied, including prodrug, dendrimer-based drug delivery, antibody-drug conjugate (ADC), and proteolysis targeting chimera (PROTAC); and amazingly, each of these approaches has resulted in a drug candidate entering clinical trials. We envision technologies like ADC and PROTAC could also be utilized to increase the therapeutic index of MCL-1 inhibitors.